Enveric Biosciences, Inc. Common Stock (ENVB) Stock Price

ENVBStock

$1.37−90.94%52W

Market Cap$6.13M

P/E—

PEG Ratio—

Div yield—

Beta1.25

ENVB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-49.66%

Price vs S&P 500 (4W)-15.92%

VGM Score40.67

Book Value / Share (Quarterly)$2.68

P/TBV (Annual)2.35x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)3.35%

Cash Flow / Share (Quarterly)$-4.24

Price vs S&P 500 (YTD)-75.08%

Gross Margin (TTM)20.42%

Net Profit Margin (TTM)-14.05%

EPS (TTM)$-22.04

10-Day Avg Trading Volume0.17M

EPS Excl Extra (TTM)$-22.04

EPS (Annual)$-26.21

ROI (Annual)-209.98%

Gross Margin (Annual)20.42%

Net Profit Margin (5Y Avg)-18.30%

Cash / Share (Quarterly)$2.60

Revenue Growth QoQ (YoY)-11.87%

ROA (Last FY)-172.14%

Revenue Growth TTM (YoY)-7.16%

EBITD / Share (TTM)$-11.95

ROE (5Y Avg)-408.09%

Operating Margin (TTM)-15.88%

Cash Flow / Share (Annual)$-7.67

P/B Ratio1.10x

P/B Ratio (Quarterly)0.72x

Net Income / Employee (Annual)$-1,754,400

EV / Revenue (TTM)0.02x

Net Interest Coverage (TTM)-79744.36x

ROA (TTM)-177.47%

EPS Incl Extra (Annual)$-26.21

Current Ratio (Annual)5.38x

Quick Ratio (Quarterly)10.66x

3-Month Avg Trading Volume0.81M

52-Week Price Return-90.94%

Revenue / Employee (TTM)$7,984,000

Tangible BV / Share (Quarterly)$8.66

P/S Ratio (Annual)0.14x

Asset Turnover (Annual)1.58x

52-Week High$17.52

Operating Margin (5Y Avg)-16.30%

EPS Excl Extra (Annual)$-26.21

Tangible BV CAGR (5Y)-26.11%

26-Week Price Return-37.73%

Quick Ratio (Annual)5.14x

13-Week Price Return-40.95%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.67x

Enterprise Value$650,900

Asset Turnover (TTM)1.43x

Book Value / Share Growth (5Y)-25.46%

Revenue / Employee (Annual)$7,982,000

Inventory Turnover (Annual)2.60x

Pretax Margin (Annual)-13.08%

Cash / Share (Annual)$4.41

3-Month Return Std Dev71.42%

Gross Margin (5Y Avg)23.50%

Net Income / Employee (TTM)$-1,644,100

ROE (Last FY)-209.98%

Net Interest Coverage (Annual)-9332.56x

EPS Basic Excl Extra (Annual)$-26.21

P/FCF (TTM)32.70x

Receivables Turnover (TTM)5.60x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-22.04

Receivables Turnover (Annual)5.60x

ROI (TTM)-220.99%

P/S Ratio (TTM)0.14x

Pretax Margin (5Y Avg)-18.38%

Revenue / Share (Annual)$3991.00

Tangible BV / Share (Annual)$27.44

Price vs S&P 500 (52W)-109.50%

Year-to-Date Return-62.26%

5-Day Price Return-2.84%

EPS Normalized (Annual)$-26.21

ROA (5Y Avg)-232.54%

Net Profit Margin (Annual)-14.03%

Month-to-Date Return-12.74%

Cash Flow / Share (TTM)$-10.58

EBITD / Share (Annual)$-25.61

Operating Margin (Annual)-15.84%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-408.09%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-22.04

P/TBV (Quarterly)1.37x

P/B Ratio (Annual)0.52x

Inventory Turnover (TTM)19.00x

Pretax Margin (TTM)-13.05%

Book Value / Share (Annual)$3.94

Price vs S&P 500 (13W)-42.90%

Beta1.25x

P/FCF (Annual)16.85x

Revenue / Share (TTM)$3992.00

ROE (TTM)-220.99%

52-Week Low$1.17

vGradeB

gGradeD

mGradeF

vgmGradeC

ENVB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2024	Mar 28, 2025	-$2.76	-$2.03	+26.38%(+$0.73)
Q3 2024	Nov 14, 2024	—	-$43.20	—
Q2 2024	Aug 12, 2024	-$99.00	-$45.00	+54.55%(+$54.00)
Q1 2024	May 15, 2024	-$139.50	-$109.80	+21.29%(+$29.70)

ENVB Analyst Recommendations

Nov 2025

Dec 2025

Jan 2026

Feb 2026

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ENVBEnveric Biosciences, Inc. Common Stock	B	D	F	$1.37
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Enveric Biosciences, Inc. Common Stock

Enveric Biosciences develops novel small-molecule therapeutics targeting depression, anxiety, addiction, and other psychiatric disorders through neuroplastogenicity. Its lead program, EB-003, is a first-in-class candidate designed to promote neuroplasticity without inducing hallucinations. The company is also advancing EB-002, a synthetic psilocin prodrug, as a next-generation treatment for psychiatric disorders.